Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO

Oct 16, 2024, 08:55 AM

Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.